CD274 and neoplasm: Among patients with at least 50% of tumor cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (14.9 months vs 8.2 months; p = 0.0002) and with pembrolizumab 10 mg/kg than with docetaxel (17.3 months vs 8.2 months; p < 0.0001).